Cho Plus
Business Services · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
329 Oyster Point Blvd, South San Francis...Website
www.cho-plus.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Cho Plus
CHO Plus specializes in enhancing therapeutic protein and virus production through genetically engineered mammalian cell lines. Their patented technology has achieved a tenfold increase in protein productivity compared to standard cell lines, significantly lowering production costs. The company aims to reduce the need for costly manufacturing infrastructure in the biopharmaceutical industry. CHO Plus targets clients in the biotechnology and pharmaceutical sectors seeking efficient production solutions.Explore more
Cho Plus Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cho Plus your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Cho Plus
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Cho Plus, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Cho Plus has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Cho Plus launches new products
Earning: See what the market has to say on Cho Plus recently announced quarterly report
Check out if Cho Plus is spiking on competitors!
Funding: Get notified immidiatlly once Cho Plus has new funding data
Click to see if Cho Plus had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at Cho Plus
Find 3 more new buyers
Compare Similar Companies to Cho Plus
Compare insights from companies similar to Cho Plus, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Cho Plus is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Cho Plus is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Cho Plus.
Cho Plus Tech Stack
A closer look at the technologies used by Cho Plus
Most Recent Scoops
Project
Product Management, Intellectual Property, Legal Affairs, Bioengineering
Project
Product Development, Product Management, Intellectual Property, Legal Affairs, Bioengineering
New Hire
Executive Move
New Hire
Executive Move
Cho Plus News & Media
CHO Plus Enters into Project Agreement with BARDA’s BioMaP Consortium to Develop High Productivity Cell Lines for Filovirus Monoclonal Antibody Production
CHO Plus awarded biomanufacturing contract from BARDA's BioMaP Consortium to develop high productivity cell linesCHO Plus Selected for 2025 BioTools Innovator Accelerator Program
CHO Plus, a leading developer of biopharmaceutical manufacturing technology, announced its selection for the 2025 BioTools Innovator AcceleratorU.S. Patent Issued for a Family of Sleeping Beauty Soluble Protein Cell Transfection Agents
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--CHO Plus, Inc. (www.CHO-Plus.com), a leading developer of biopharmaceutical manufacturing technology, announces that U.S. Patent No. 12,270,055 was issued today by the United States Patent and Trademark Office. EMBLEM Technology Transfer GmbH has licensed the patented technology to CHO Plus for transfecting cells to produce therapeutic agents. The patent covers a family of variants of Sleeping Beauty transposase that were developed by Dr. Orsolya BaCHO Plus Obtains U.S. Patent for Improved Production of Viral Vectors for Gene Therapy
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--CHO Plus, Inc. (www.CHO-Plus.com), a leading developer of biopharmaceutical manufacturing technology, announced that U.S. Patent No. 12,252,713 was issued by the United States Patent and Trademark Office. The patent covers a procedure for fusing and screening cells to obtain cell hybrids that can be used to produce viral vectors for gene therapy. This is the first patent covering the use of cell hybrids to produce viral vectors. Adoption of CHO Plus
Read more news
Top Business Services Companies
Frequently Asked Questions Regarding Cho Plus
Sign Up For FreeTo access detailed company insights
CHO Plus specializes in enhancing therapeutic protein and virus production through genetically engineered mammalian cell lines. Their patented technology has achieved a tenfold increase in protein productivity compared to standard cell lines, significantly lowering production costs. The company aims to reduce the need for costly manufacturing infra... Read More
